| 000 | 01756 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513225056.0 | ||
| 264 | 0 | _c20010215 | |
| 008 | 200102s 0 0 eng d | ||
| 022 | _a1019-6439 | ||
| 024 | 7 |
_a10.3892/ijo.18.1.25 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRamamoorthy, P | |
| 245 | 0 | 0 |
_aIn vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. _h[electronic resource] |
| 260 |
_bInternational journal of oncology _cJan 2001 |
||
| 300 |
_a25-32 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAmino Acid Substitution |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aArginine _xgenetics |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aCaspase 3 |
| 650 | 0 | 4 |
_aCaspases _xmetabolism |
| 650 | 0 | 4 |
_aCell Division _xdrug effects |
| 650 | 0 | 4 |
_aCisplatin _xpharmacology |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aEnzyme Activation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlycine _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPoint Mutation |
| 650 | 0 | 4 |
_aProlactin _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTransforming Growth Factor alpha _xmetabolism |
| 650 | 0 | 4 |
_aTransforming Growth Factor beta _xmetabolism |
| 650 | 0 | 4 | _aTransforming Growth Factor beta1 |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aSticca, R | |
| 700 | 1 | _aWagner, T E | |
| 700 | 1 | _aChen, W Y | |
| 773 | 0 |
_tInternational journal of oncology _gvol. 18 _gno. 1 _gp. 25-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3892/ijo.18.1.25 _zAvailable from publisher's website |
| 999 |
_c11056712 _d11056712 |
||